Randomized Phase IIa Clinical Study of an Anti-αvβ6 Monoclonal Antibody in Idiopathic Pulmonary Fibrosis
- PMID: 35830489
- PMCID: PMC9704833
- DOI: 10.1164/rccm.202205-0868LE
Randomized Phase IIa Clinical Study of an Anti-αvβ6 Monoclonal Antibody in Idiopathic Pulmonary Fibrosis
Figures
Comment in
-
Goldilocks and the Three Trials: Clinical Trials Targeting the αvβ6 Integrin in Idiopathic Pulmonary Fibrosis.Am J Respir Crit Care Med. 2022 Nov 1;206(9):1062-1063. doi: 10.1164/rccm.202208-1579ED. Am J Respir Crit Care Med. 2022. PMID: 36018580 Free PMC article. No abstract available.
References
-
- Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med . 2018;198:e44–e68. - PubMed
-
- Tatler AL, Jenkins G. TGF-β activation and lung fibrosis. Proc Am Thorac Soc . 2012;9:130–136. - PubMed
-
- Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell . 1999;96:319–328. - PubMed
-
- Horan GS, Wood S, Ona V, Li DJ, Lukashev ME, Weinreb PH, et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med . 2008;177:56–65. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
